乳腺癌VEGF与E2的检测及相关性研究  

Clinical Value of the Detection of Vascular Endothelial Growth Factor and Estrogen with Breast Cancer

作　　者：韦庆文[1] 迟秀文[2] 蓝宇萍[1] 黄震[1] 罗丹[1] 

机构地区：[1]深圳市龙岗中心医院,广东深圳518116 [2]广东医学院,广东东莞523808

出　　处：《现代检验医学杂志》2012年第3期66-68,73,共4页Journal of Modern Laboratory Medicine

摘　　要：目的探讨血管内皮生长因子（VEGF）在乳腺癌组织中的表达及检测乳腺癌患者血清中VEGF与雌激素（E2）的含量对诊断乳腺癌的意义。方法选取龙岗中心医院普外科2007-2010年乳腺癌标本42例。组织学分级：Ⅰ级7例，Ⅱ级21例，Ⅲ级14例。有淋巴结转移者29例，无淋巴结转移者13例。同时取乳腺良性病变26例，以上患者术前均未经任何治疗。正常对照组为36例来自体检正常的健康女性。选择VEGF单克隆抗体及超敏（鼠）S-P试剂盒利用免疫组化技术检测42例乳腺癌组织中VEGF蛋白表达。所有受试者均于晨起空腹采血，同时用化学发光法检测血清中VEGF与E2的含量。采用SPSS13统计分析软件处理数据，组间用t检验对实验数据进行处理，分析VEGF与E2两种指标与临床指标的关系。结果乳腺癌组织中VEGF表达阳性率为60．95％，VEGF表达阴性者癌周淋巴结较少，癌间质内皮细胞不表达或呈弱阳性表达。乳腺癌患者VEGF与E2值分别为160．58±14．37ng／ml和199．26±49．31pg／ml，t值47．250，P值0.024；乳腺良性病变组VEGF与E2值分别为78．30±9．12ng／ml和107．41±38．86pg／ml，t值34．549，P值0．037。不同临床分期乳腺癌患者VEGF及E2浓度与TNM分期之间经方差分析，显示各项指标之间均有显著性差异。Ⅰ期乳腺癌VEGF与E2值分别为137．17±13．63ng／ml和112．69±33．57pg／ml；Ⅱ期乳腺癌VEGF与E2值分别为226．70±23．47ng／ml和171．16±37．61pg／ml，t值31．035，P值0．032；Ⅲ期乳腺癌VEGF与E2值分别为374．86±36．59ng／ml和250．20±41．43pg／ml，t值41．548，P值0．020。且有淋巴结转移的乳腺癌患者VEGF与E2值分别为128．40±12．19ng／ml和79．63±35．90pg／ml，t值25．370，P值0．047；而无淋巴结转移的乳腺癌患者VEGF与E2值分别为267．12±30．25ng／ml和187．66±41．34pg／ml，且E2，VEGF水平呈正相关（P〈0．05），乳腺癌患�Objective To investigate the clinical diagnosis value with the breast cancer by the expression of Vascular endothelial growth factor （VEGF） and by detectining the levels of VEGF, Estrogen （E2） in the breast cancer tissue. Methods 42 cases of breast cancerspecimens were selected from the Longgang Central Hospital of general surgery from 2007 to 2010 and histological grade：7 cases of grade Ⅰ ,21 cases of grade Ⅱ ,14 cases of grade Ⅲ ,29 cases with lymph node metastasis,13 cases without lymph node metastasis. At the same time 26 cases were take nfrom benign breast lesions. The above patients were without any tretment. The normal control group of 36 cases from the examination of normal healthy women. VEGF monoclonalantibody and hypersensitivity （mouse） SP Kitimmunohistochemistry wereusedtodetecte VEGF protein expression of breast cancer tissue in 42 cases. All subjects were drawn blood in the early morning and serum VEGF and E2 content were tested by chemiluminescence. At the same time SPSS13 statistical analysis software was adopted to process data between the groups t-test used to process theexperimentaldataand analysis the relationship between the two indicators VEGF and E2 and clinical significance. Results VEGF expression in breast cancer positive rate was 60.95 ± ;VEGF in lymph node-negative cancers had less expression. Breast cancer patients with serum VEGF, E2 levels were significantly higher than the normal benign breast disease group and control group and VEGF,E2 levels were positive lycorrelated. Inbreast cancer patients,VEGF and E2 values were 160. 58±14.37 ng/ml and 199. 26±49.31 pg/ml respectively, t=47. 250, P =0. 024. In benign breast lesions, VEGF and E2 values were 78.30 ± 9.12 ng/ml and 107.41 ± 38.86 pg/ml respectively, t= 34. 549, P= 0. 037 and VEGF and E2 values were 54. 62±7.73 ng/ml and 81. 57±25.14 pg/ml respectively in normal control group. Furthermorethere were significant differences between the display indicatorsin different clinical stages of breast cancer pati

关 键 词：乳腺癌 血管内皮生长因子 雌激素 

分 类 号：R730.43[医药卫生—肿瘤]